BioCorRx Inc. (OTC: BICX), a developer and provider of innovative treatment support programs for substance use disorders and related conditions, announced on September 10, 2026, the appointment of Richard J. Baum to its Strategic Advisory Board. Baum is a former Acting Director of the White House Office of National Drug Control Policy (ONDCP) and former Executive Director of the President’s Commission on Combating Drug Addiction and the Opioid Crisis. He brings nearly three decades of experience in national drug policy, addiction, public health, law enforcement, and justice policy.
During 28 years at ONDCP, Baum served across six presidential administrations and helped shape federal responses to evolving drug threats, including the opioid crisis. His experience spans treatment and recovery policy, prevention, public safety, interagency coordination, and collaboration with state and local partners. BioCorRx Inc. expects to draw on Baum’s policy and systems-level expertise as the Company advances its treatment and pharmaceutical strategies, including LUCEMYRA® (lofexidine), an FDA-approved non-opioid medication indicated for the mitigation of opioid withdrawal symptoms to facilitate abrupt opioid discontinuation in adults, and BICX104, the Company’s investigational biodegradable naltrexone implant technology.
“Rich has spent his career at the intersection of drug policy, public health, treatment, and public safety, and we are honored to welcome him to BioCorRx,” said Lourdes Felix, Chief Executive Officer of BioCorRx Inc. “His deep understanding of how policy translates into real-world treatment access will be invaluable as we work to expand awareness of evidence-based approaches to addiction treatment and thoughtfully position our programs within the broader continuum of care.”
“I am pleased to join BioCorRx as a strategic advisor at a time when the country continues to face significant challenges related to opioid use, addiction treatment, and recovery,” said Richard J. Baum. “BioCorRx is working across several important points in the treatment continuum, including managing opioid withdrawal symptoms with LUCEMYRA. In an era of increasingly dangerous polysubstance use, particularly involving illicit fentanyl and methamphetamine, I am also encouraged by the Company’s research evaluating BICX104, an investigational long-duration naltrexone implantable pellet, as a potential treatment for methamphetamine use disorder. I look forward to helping BioCorRx position these approaches within a comprehensive, evidence-based system of care that expands treatment access, supports retention, and improves long-term recovery.”
The appointment comes as the U.S. continues to grapple with high rates of substance use disorders. According to the 2025 National Survey on Drug Use and Health, an estimated 4.0 million people in the United States aged 12 or older had an opioid use disorder in the past year, and approximately 2.7 million reported using methamphetamine in the past year. Baum’s expertise in policy and public health could help BioCorRx navigate regulatory and reimbursement landscapes, potentially accelerating access to its treatments.
BioCorRx’s pipeline includes LUCEMYRA, which is already FDA-approved, and BICX104, which is currently being evaluated in a clinical study supported by the National Institute on Drug Abuse (NIDA) of the National Institutes of Health under Award Number U01DA059994. The study, which commenced in January 2026, is assessing BICX104 alone and in combination with bupropion as a potential treatment for methamphetamine use disorder. For more information, visit www.BioCorRx.com.
Baum is also an Adjunct Professor at Georgetown University’s McCourt School of Public Policy and the author of Inside America’s Opioid Crisis: 12 Hard Lessons for Today’s Drug War. He serves on the United Against Fentanyl Board of Directors. His addition to BioCorRx’s advisory board signals the company’s intent to bridge policy and treatment innovation, a move that could influence how addiction therapies are adopted and funded. As the opioid and methamphetamine crises persist, BioCorRx’s efforts to expand treatment options may offer new hope for patients and providers alike.
